olfactory receptor family 52 subfamily E member 3 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR52E3P profile across patient tissues and cancer cell-line models. OR52E3P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR52E3P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, OR52E3P RNA expression shows 4,283 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, PRAD, and UCEC as cancer lineages where OR52E3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52E3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52E3P survival associations across molecular data types. OR52E3P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52E3P RNA expression–survival associations across cancer types. High OR52E3P expression shows unfavorable associations in KIRC, OV, HNSC, KICH, MESO and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for OR52E3P RNA expression.
This table summarizes OR52E3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR52E3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52E3P shows higher tumor expression in PRAD. The PRAD box plot shows higher OR52E3P RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .030).
This table shows molecular features associated with OR52E3P in patient tissues and cancer cell lines. In patient samples, OR52E3P shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
